<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765930</url>
  </required_header>
  <id_info>
    <org_study_id>MelaPRP2020</org_study_id>
    <nct_id>NCT04765930</nct_id>
  </id_info>
  <brief_title>Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma</brief_title>
  <official_title>Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in the Treatment of Melasma: A Split Face Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melasma is a common, acquired, esthetically disfiguring hypermelanosis of the face. Melasma&#xD;
      is considered a disappointing challenge when treatment options are addressed. Diverse&#xD;
      treatment modalities such as retinoic acid, hypo-pigmenting agents like hydroquinone, azelaic&#xD;
      acid, and kojic acid, chemical peels, microdermabrasion, and lasers have been tried for the&#xD;
      treatment of melasma. There is no universally proven therapy that induces and maintains&#xD;
      remission of the condition. Q-switched: Nd YAG laser toning and platelet rich plasma (PRP)&#xD;
      are promising treatments for melasma.The aim of this work is evaluate the efficacy and safety&#xD;
      of combined PRP and Q-switched: NdYAG laser in the treatment of melasma using clinical&#xD;
      assessment, in addition to assessment of Melanin Index and Erythema Index.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemi-Melasma Area and Severity Index (MASI) score</measure>
    <time_frame>2 months after final treatment</time_frame>
    <description>Hemi-Melasma Area and Severity Index(MASI) score for Pigmentation, and Area of involvement. The minimum value is 0 and the maximum value is 12. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Melanin Index</measure>
    <time_frame>2 months after final treatment</time_frame>
    <description>Objective assessment of melanin index using colorimeter apparatus. The minimum value is 0. No maximum value. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema Index</measure>
    <time_frame>2 months after final treatment</time_frame>
    <description>Objective assessment of erythema index using colorimeter apparatus. The minimum value is 0. No maximum value. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Paients' Satisfaction assessed by the VAS</measure>
    <time_frame>2 months after final treatment</time_frame>
    <description>a four-scale grading score: poor: response rate= 0-25%; fair: response rate= 25-50%; good: response rate=50-75%; excellent: response rate=75-100%</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperpigmentation</condition>
  <condition>Melasma</condition>
  <condition>PRP</condition>
  <condition>Lasers</condition>
  <arm_group>
    <arm_group_label>PRP Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of the face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Other half of the face</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Q-switched nd:YAG laser toning</intervention_name>
    <description>Q-switched nd:YAG laser toning for melasma.</description>
    <arm_group_label>PRP Injection</arm_group_label>
    <arm_group_label>Saline injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with bilateral nearly symmetric melasma on the face.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving systemic or topical or laser treatment relevant to melasma within&#xD;
             three months before enrollment into the study.&#xD;
&#xD;
          -  Use of oral or injectable contraceptives or hormone replacement therapy during&#xD;
             treatment or 12 months before&#xD;
&#xD;
          -  Patients active skin infections and active HSV&#xD;
&#xD;
          -  History of hypertrophic scars or keloids.&#xD;
&#xD;
          -  Patients with hypercoagulable state or bleeding diatheses&#xD;
&#xD;
          -  Pregnant and lactating females.&#xD;
&#xD;
          -  History of liver diseases&#xD;
&#xD;
          -  Intake of systemic chemotherapy, corticosteroids, antiplatelets or anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mona El-Kalioby, MD</last_name>
    <phone>+201224442941</phone>
    <email>mona.elkalioby@kasralainy.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Dermatology, Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona El-Kalioby, MD</last_name>
      <email>monaelkalioby@cu.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Tahra Leheta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yosra Shawky, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona El-Kalioby, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mona El-Kalioby</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>laser toning</keyword>
  <keyword>Hemi-MASI</keyword>
  <keyword>Colorimeter</keyword>
  <keyword>Erythema Index</keyword>
  <keyword>Melanin Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
    <mesh_term>Hyperpigmentation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

